Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK102 in primary hypercholesterolemia and mixed dyslipidemia (CTR20213363)
CTR20213363Phase 3Completed
- Sponsor
- Kangrong Dongfang
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ebronucimab in hypercholesterolemia, combined dyslipidaemia, sponsored by Kangrong Dongfang. Started Dec 2021; status: completed.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20213363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213363.